newsfilter
← Latest News
GlobeNewswire·

IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

IRLA
  • IRulya Therapeutics Inc. officially changed its name from Quince Therapeutics, Inc. on October 9, 2026, with common stock beginning Nasdaq trading under the ticker "IRLA" on October 12, 2026.
  • Phase 2 data for LAM-001 in bronchiolitis obliterans syndrome (BOS) is anticipated in the first quarter of 2027.
  • The company held $105.2 million in cash, cash equivalents, & investments as of September 30, 2026, which is expected to fund operations through the end of 2028.
  • LAM-001 Phase 2b trial data in pulmonary hypertension associated with interstitial lung disease (PH-ILD) is expected in the first quarter of 2028.
  • A Phase 2 study for LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH) is planned to initiate in the fourth quarter of 2026 with data anticipated in the fourth quarter of 2028.
  • Brigette Roberts, M.D., John Militello, CPA, & Keith Fandrick, Ph.D., were appointed as Chief Executive Officer, Chief Financial Officer, & Chief Operating Officer respectively.
  • The Board of Directors was strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., & Drayton Wise.
  • Series C preferred stock converted to common stock on October 9, 2026, resulting in 10,841,470 outstanding common shares as of November 5, 2026.
  • Research & development expenses for the third quarter ended September 30, 2026, were $5.9 million, down from $8.1 million in the same period of 2025.
  • General & administrative expenses for the third quarter ended September 30, 2026, were $9.0 million, up from $3.3 million in the same period of 2025.
  • The company reported a net loss of $27.7 million, or $2.31 per share, for the three months ended September 30, 2026.
  • LAM-001 is a proprietary once-daily dry powder inhaled formulation of rapamycin designed to target the mTOR pathway directly in the lungs.
Company
IRulya Therapeutics Inc.
Keywords
Nasdaq:IRLA, IRulya Therapeutics Inc.